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Enterococci, particularly Enterococcus faecalis and Enterococcus faecium, are an 
important cause of nosocomial infections and have become a major issue world-
wide. Nosocomial infections due to vancomycin resistant Enterococci (VRE) occur 
frequently. A significant increase in prevalence of VRE has been reported recently 
in many countries. Enterococci are second most frequent cause of nosocomial 
urinary tract infection, bacteremia and infective endocarditis. They are also related 
to etiology of intra-abdominal an pelvic infections, gastrointestinal infections and 
oral infections. The ability of Enterococci to survive in adverse conditions, presence 
of virulence factors and possession of intrinsic and acquired antibiotic resistance 
traits poses a therapeutic challenge. Due to high level of multidrug resistance in 
VRE, Enterococcus has become an important organism in health based settings.
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1. Introduction
Enterococci are Gram-positive, non-spore forming and facultative anaerobic 
cocci. They are indigenous flora of the intestinal tract, oral cavity and vagina in 
healthy persons. The genus comprises 54 species which are ubiquitously present in 
nature [1]. Enterococci have emerged as an important nosocomial pathogens second 
to Staphylococci which is the leading cause of nosocomial infections worldwide [2]. 
Enterococci are important nosocomial pathogens causing up to 10% of all infections 
in the hospitalized patients [3]. In these Enterococci infections approximately 60% 
of infections are caused by Enterococcus faecalis and Enterococcus faecium causes the 
remaining [4]. In the last decade both E. faecalis and E. faecium have emerged as 
important nosocomial pathogens. Other Enterococcal species causing nosocomial 
human infections are E. avium, E. gallinarum, E. casseliflavus, E. durans, E. raffinosus 
and E. mundtii. Majority of clinical isolates (63–81%) are identified as E. faecalis, 
around 13–23% as E. faecium and other enterococcal species comprise around 3–4% 
of the clinical isolates [5].
2. Prevalence of vancomycin resistant Enterococci (VRE)
Nosocomial infections particularly by vancomycin resistant Enterococci (VRE) 
have become a major problem since last few years though VRE are organisms of 
low virulence and pathogenicity. Nosocomial infections caused by VRE are highly 
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prevalent in intensive care units of hospitals. These infections are particularly high 
in presence of underlying health factors like diabetes, liver transplantation, neutro-
penia, diabetes mellitus and renal dysfunction. Recently it has also been seen that 
VRE bloodstream infections have higher mortality rates as compared to vancomycin 
susceptible Enterococci (VSE) [6, 7]. Data from countries like Germany shows an 
increase of VRE from less than 5% in 2001 to 14.5% in 2013 mainly vancomycin 
resistant E. faecium [8]. In Europe of all the nosocomial infections reported 9.6% 
were of Enterococci [9]. In USA 3% of the nosocomial infections are due to VRE 
[10]. VRE nosocomial infections cause greater number of invasive treatment result-
ing in extended stay in hospital and cost [11]. Hospitals in some countries have now 
established VRE screening in high risk areas and isolation of patients to prevent 
spread of the resistant pathogen [12]. A study has shown the prevalence of VRE 
colonization in patients who had history of previous administration of antibiotics 
for more than 2 weeks were 10 times more likely of getting VRE colonization [13]. 
Other studies have also reported similar findings which show antibiotic exposure 
can cause colonization of VRE in hospital settings because of their resistance to 
commonly used antibiotics, virulence factors and ability to acquire genes [14].
3. Genetic factors and antibiotic resistance in VRE
The genes Van A, Van B, Van C, Van D and Van E are responsible for vancomycin 
resistance in Enterococci. Van M has been identified which is also an important 
vancomycin resistant determinant among different E. faecium lineages in hospitals 
in Shanghai, China [15]. Each Van operon has different ecological origin, Van A 
has originated from soil organisms, van B, Van G and Van D from gut microbiota 
[16]. Vancomycin resistance in Enterococci is of two types (a) Intrinsic resis-
tance—Enterococci spp. like E. gallinarum and E. casseliflavus show an inherent low 
level resistance to Vancomycin. They have Van C genes that produce Vancomycin 
minimum inhibitory concentration (2–32 μg/ml) [17] A hospital wide outbreak of 
vancomycin resistant E. gallinarum has been reported in Colombia showing that 
uncommon species of Enterococci are capable of spreading in the hospital environ-
ment and producing nosocomial infections [18]. The second type is (b) acquired 
resistance—Enterococci species acquire resistance genes and become resistant 
to vancomycin. This is seen in E. faecium and E. faecalis and to some extent in E. 
raffinosus, E. avium, E. durance and other enterococcal species. The most com-
mon isolated Enterococci species which is VRE in hospital settings is E. faecium. 
It has been seen that E. faecium produces high vancomycin minimum inhibitory 
concentration (64–1000 μg/ml) [19]. There has been a significant increase in VRE 
prevalence. The emergence and rapid spread of VRE has led to the use of new 
antibiotics like linezolid, daptomycin and tigecycline. Linezolid is a oxazolidinone 
antibiotic. An oxazolidinone resistance gene optr A has been identified in E. faecalis 
and E. faecium isolates of human and animal origin [20] .Linezolid resistance is still 
less prevalent reported as 1.1 and 1.8% in E. faecium and E. faecalis isolates from 19 
US hospitals [21]. Daptomycin resistance is more prevalent in E. faecium than E. 
faecalis isolates. Around 3.9 and 0.2% of E. faecium and E. faecalis isolates have been 
reported in various hospital settings [22]. Tigecycline is a semisynthetic deriva-
tive of tetracycline. Tigecycline resistance in E. faecium and E. faecalis is rare and 
reported as 0.3%. It is being used to treat bacteremia caused by MDR enterococci. 
The increased use of antibiotics in hospitals is causing gut dysbiosis and enterococci 
possess surviving ability take over the niche in the gastrointestinal tract and this 
could be the primary source of enterococcal infections [23].
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4. Lineages of nosocomial Enterococci
The ability of E. faecium to exchange mobile genetic elements carrying anti-
microbial resistance genes and virulence determinants has resulted in hospital 
adapted clones [24]. Esp was the first adaptive element found in hospital strains of 
E. faecium. The E. faecium esp. gene has been linked to biofilm formation, UTI and 
endocarditis [24]. New determinants have been now linked to hospital isolates of E. 
faecium. A genomic analysis study of E. faecium hospital strains identified gain and 
loss of gene clusters in clinical and non-clinical isolates of E. faecium [25]. Genomic 
studies of nosocomial E. faecium infection have confirmed the transmission of 
E. faecium Clad A115. Recently it has been seen a significant presence of hospital 
associated VRE fm lineages in the wastewater and need of controlling healthcare 
associated dissemination of VRE fm [26]. However studies on E. faecalis ecotypes 
have shown no appearance of distinct E. faecalis strains over a significant period of 
time. Virulence factors like antibiotic resistance and virulence genes, esp., capsule 
polysaccharide genes and genes determining gelatinase, aggregation factor, cytoly-
sin and ace are identified in E. faecalis isolates [27]. The non-emergence of distinct 
ecotypes of E. faecalis and multiplicity of closely related ecotypes is not seen in E. 
faecalis as compared to E. faecium. A genomic analysis of 168 E. faecalis hospital 
isolates showed no genes and non-synonymous single nucleotide polymorphisms 
in the three lineages of hospital strains [28]. A recent study has also demonstrated 
that the acquisition of mobile genetic elements in E. faecalis V583, makes it unable to 
coexist with commensal enterococci in humans [29].
5. Nosocomial infections by VRE
Nosocomial infections by Enterococci are Urinary tract infection, endocarditis, 
bacteremia, catheter related infections, wound infections, intra- abdominal and 
pelvic infections and recently even oral infections have been reported.
6. Urinary tract infection (UTI)
Enterococci cause both uncomplicated and complicated health care associ-
ated UTI. E. faecalis. Vancomycin resistant E. faecalis and vancomycin resistant E. 
faecium have been mainly implicated in Enterococcal UTI. VRE is fast becoming 
a major cause of health care associated UTI. The treatment of UTI involves the 
use of broad spectrum antibiotics which is a major cause of resistant strains to 
vancomycin (VRE). The complications range from uncomplicated cystitis, pyelo-
nephritis, perinephric abscess, and prostatitis. These organisms are responsible for 
nosocomial infection of urinary tract particularly in intensive care units (ICU). 
Enterococci have been particularly reported in catheter associated urinary tract 
infections, CAUTI (28.4%). Enterococci species are capable of producing biofilms, 
which are a population of cells attached irreversibly on various biotic and abiotic 
surfaces. CAUTI are associated with multispecies biofilms. Biofilms are difficult to 
remove and result in many chronic infections. Bacteria in biofilms colonize medi-
cal devices such as catheters, pacemakers, prosthetic heart valves and orthopedic 
appliances [30]. These multispecies biofilms have synergistic or antagonistic effects 
of interspecies interaction. Many studies have shown the association of biofilm 
producing enterococci and urinary catheter [31, 32]. Enterococci biofilms which 
are formed on catheter in CAUTI are resistant to immune clearance, urination 
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force and even antibiotics. These enterococci utilize fibrinogen formed on catheter 
surface and form resistant biofilms. E. faecalis attachment in biofilm formation 
seen in vitro is partially inhibited by uropathogenic E. coli (UPEC) but biofilm 
formation by K. pneumoniae or UPEC are not affected by E. faecalis but E. faecalis 
increased E. coli biofilm mass accumulation and it has been seen that co-culture of 
an E. faecium probiotic strain with enteropathogenic E. coli increased the antibiotic 
sensitivity of E. coli to aminoglycosides, B-lactams and quinolones [33]. Biofilm 
formation confers the organism resistance to phagocytosis and antimicrobial 
agents. UTI by E. faecalis is mediated by virulence factors of the genes esp., srtC, 
ebp A, ebpC, ace, epaB, msrA, msr B, sigV, efbA, and grvR/etaR. E. faecium also 
displays similar genes related to virulence. Both E. faecalis and E. faecium isolated 
from nosocomial UTIs show kidney tropism. It is important to study factors in 
enterococcal causing pyelonephritis [33].
7. Bacteremia
There is a high prevalence of blood stream infections caused by Gram-positive 
bacteria and 45% are caused by Enterococci. Bacteremia is a common manifesta-
tion of vancomycin resistant Enterococci. Due to use of intravascular and urinary 
catheters these nosocomial infections are acquired. E. faecium in the blood stream 
is associated with increased mortality due to high levels of resistance. Risk factors 
identified with VRE bacteremia include intestinal colonization, long term anti-
biotic use, severity of illness, bone marrow transplant, hematologic malignancy, 
indwelling urinary catheters, corticosteroid treatment, chemotherapy and par-
enteral nutrition [34]. Studies have shown that bacteremia caused by vancomycin 
resistant Enterococci strains carry higher mortality rates (2.5-fold increase) as 
compared to bacteremia caused by vancomycin sensitive strains. In one such study 
the prognosis of VRE bacteremia was not much changed even with the availability 
of antimicrobial agents with greater potency. E. faecalis sigma factor Sig V that 
regulates gene expression in response to stress conditions has been implicated in 
enterococci survival and colonization in systemic infection. Absence of sig V in 
systemic infection in mice resulted in attenuation of bacterial translocation reduc-
ing colonization of kidney and liver. Virulence factors like Bgs A and Bgs B have 
also been implicated in colonization of endocarditic lesions and bacteremia. BgsA 
and Bgs B are now being used to treat enterococcal infections by using them as drug 
targets [35]. Similarly gene Asr has been implicated in E. faecium pathogenesis in 
systemic infections. Nosocomial enterococcal bacteremia have been associated with 
urinary catheters, intra-abdominal, burn wound, pelvic, biliary and bone sources. 
VRE bacteremia results in 2.5-fold increase in mortality as compared to vancomycin 
sensitive (VSE) bacteremia [18].
8. Infective endocarditis
Enterococci are the second most cause of infective endocarditis. Endocarditis 
caused by VRE faecalis causes GI or GU manipulation, damaged mitral or aor-
tic valve infections, liver transplantation whereas VRE faecium endocarditis is 
associated with infection of tricuspid valve [36]. E. faecalis is also associated with 
community acquired endocarditis. Characteristic signs of infection include fever 
or a new murmur. Typical stigmata of endocarditis like petechiae, osler spots are 
rare and occur with sub-acute infections. Genitourinary infection or instrumenta-
tion often precedes the onset of enterococcal endocarditis. In published series of 
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enterococcal endocarditis men often outnumber women and mostly it occurred in 
elderly individuals. In the current therapeutic regimes, the mortality rate of entero-
coccal endocarditis remains around 20%.
9. Intra-abdominal and pelvic infections
VRE has been isolated from intra-abdominal and pelvic infections. The usual 
infections include abscesses wounds or peritonitis. Often it is a part of polymi-
crobial infection with Gram negative or anaerobic organisms. Usually infecting 
strains originate from patients intestinal flora and cause intra-abdominal infection. 
Enterococci are able to cause monomicrobial peritonitis infections particularly in 
patients undergoing chronic peritoneal dialysis or liver cirrhosis.
10. Gastrointestinal infections (GI)
GI related enterococcal infections are opportunistic infections particularly 
occurring during colorectal surgery and colorectal cancer. Pre-colonization with 
VRE in patients can result in bacteremia following antibiotic induced disruption of 
gut microbiota [37]. Reg IIIy, a c type lectin is secreted by intestinal epithelial and 
paneth cells that removes Gram positive bacteria from the gut. Antibiotic treatment 
causes Reg IIIy down-regulation [38]. Therapeutic strategies have been devised to 
prevent intestinal colonization of resistant enterococci, introducing probiotic E. 
faecalis pheromone induced killing of drug resistant E. faecalis reactivating Reg IIIy 
introducing obligate anaerobic commensal bacteria containing Barnesiella species 
which prevents E. faecium gut colonization and bacteremia [39]. High collagenase 
producing E. faecalis strains have been found to be associated with colorectal 
anastomotic leak by activating tissue matrix metalloproteinase 9 that cleaves host 
extracellular matrix [40]. Enterococci produce menaquinone and extracellular 
superoxide in intestine. This results in high oxidative stress which is linked with 
colorectal cancer as high genomic instability of intestinal tumor cells as around 80% 
of colon cancers are caused due to genetic mutations.
11. Central nervous system infections (CNS)
Although CNS infections have been reported rarely with VRE but occur in 
elderly patients having underlying health issues like malignancies, pulmonary and 
cardiac complications [41]. In them VRE faecium is reported at 82% and less so of 
VRE faecalis. These infections present as fever, mental disorientation, focal CNS 
deficits and petechial rash. CSF investigations show pleocytosis, low glucose and 
increased protein levels.
12. Skin and skin structure infections (SSSE)
Enterococci are part of polymicrobial infections which are found to be associ-
ated with SSSE [42]. Enterococci are frequently isolated from diabetic foot ulcers 
and 2–5% of patients undergoing inpatient surgery. In studies using animal models 
it has been seen that E. faecalis capsular polysaccharide in SSSI predominantly is 
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13. Oral infections
Enterococci are inhabitants of the oral cavity and as opportunistic pathogen 
cause oral diseases like caries, endodontic infections, periodontitis and peri-implan-
titis. In endodontic infections the failure of root canal treatment by endodontic 
infections is now well evidenced. Enterococci have high resistance to endodontic 
medicaments and forms resistant biofilms. This is implicated in root canal treatment 
failure [43, 44]. Enterococci prevalence is also seen in gingivitis and periodontitis 
(3.7–35%) [45]. Oral Enterococci constitute the highest percentage of virulent genes 
and ability to form resistant biofilms. The oral cavity may hence be an important 
reservoir of virulent antibiotic resistant enterococci strains. VRE colonization 
occurs mainly in GI tract, skin, genitourinary tract and oral cavity. Enterococci can 
persist from months to years. The hands of health care workers are the most com-
mon source of transmission in nosocomial infections [46]. The need of oral care is 
particularly important in nosocomial settings. The spread of the nosocomial VRE 
occurs and when the immunity is lowered VRE multiply to cause disease. Few stud-
ies have shown that antibiotic resistant enterococci is transmitted by food [47–49] 
but recently Vidana et al. [50] have said there is no food related transmission of 
enterococci. Enterococci are now showing a high degree of resistance to tetracy-
cline, chloramphenicol, erythromycin besides vancomycin pose a threat for spread 
of nosocomial infection particularly in patients of ICUs and on mechanical ventila-
tors [51]. Vancomycin resistance is an independent predictor for the overall increase 
of hospital costs for the patient but also for the individual hospital [52].
14. Conclusion
VRE and have now become an important nosocomial pathogen globally. VRE 
causes range of infections from UTI, bacteremia, infective endocarditis, intra-
abdominal and pelvic infections, central nervous system infections and even oral 
infections. The ability of enterococci to form recalcitrant biofilms, colonize and 
express virulence factors, genome plasticity, resistant to antibiotics, survival ability 
makes it an important nosocomial pathogen to which new therapeutic strategies have 
to be devised for the treatment of VRE. A periodic surveillance of VRE in hospitals 
is essential for limiting the spread of antibiotic resistance. Future therapy should be 
targeted to prevent VRE colonization of patients with immunosuppression.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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